283 related articles for article (PubMed ID: 26191952)
21. Allogeneic Stem Cell Transplantation in Patients With FLT3-ITD Mutated AML: Transplantation in CR1 Is the Decisive Factor for Good Outcome.
Jindra P; Raida L; Karas M; Szotkowski T; Lysák D; Hrabětová M; Jungová A; Steinerová K; Faber E; Papajík T
Clin Lymphoma Myeloma Leuk; 2019 Jul; 19(7):462-469. PubMed ID: 31109905
[TBL] [Abstract][Full Text] [Related]
22. Comparative value of post-remission treatment in cytogenetically normal AML subclassified by NPM1 and FLT3-ITD allelic ratio.
Versluis J; In 't Hout FE; Devillier R; van Putten WL; Manz MG; Vekemans MC; Legdeur MC; Passweg JR; Maertens J; Kuball J; Biemond BJ; Valk PJ; van der Reijden BA; Meloni G; Schouten HC; Vellenga E; Pabst T; Willemze R; Löwenberg B; Ossenkoppele G; Baron F; Huls G; Cornelissen JJ
Leukemia; 2017 Jan; 31(1):26-33. PubMed ID: 27416910
[TBL] [Abstract][Full Text] [Related]
23. Hematopoietic cell transplantation in patients with intermediate and high-risk AML: results from the randomized Study Alliance Leukemia (SAL) AML 2003 trial.
Schetelig J; Schaich M; Schäfer-Eckart K; Hänel M; Aulitzky WE; Einsele H; Schmitz N; Rösler W; Stelljes M; Baldus CD; Ho AD; Neubauer A; Serve H; Mayer J; Berdel WE; Mohr B; Oelschlägel U; Parmentier S; Röllig C; Kramer M; Platzbecker U; Illmer T; Thiede C; Bornhäuser M; Ehninger G;
Leukemia; 2015 May; 29(5):1060-8. PubMed ID: 25434303
[TBL] [Abstract][Full Text] [Related]
24. Sorafenib Therapy Is Associated with Improved Outcomes for FMS-like Tyrosine Kinase 3 Internal Tandem Duplication Acute Myeloid Leukemia Relapsing after Allogeneic Hematopoietic Stem Cell Transplantation.
Xuan L; Wang Y; Chen J; Jiang E; Gao L; Wu B; Deng L; Liang X; Huang F; Fan Z; Tang X; Sun J; Zhang X; Han M; Wu D; Huang X; Liu Q
Biol Blood Marrow Transplant; 2019 Aug; 25(8):1674-1681. PubMed ID: 31009704
[TBL] [Abstract][Full Text] [Related]
25. Measurable residual disease, FLT3-ITD mutation, and disease status have independent prognostic influence on outcome of allogeneic stem cell transplantation in NPM1-mutated acute myeloid leukemia.
Al Hamed R; Labopin M; Daguindau E; Niittyvuopio R; Huynh A; Socié G; Srour M; Henri Bourhis J; Kröger N; Tholouli E; Choi G; Poiré X; Martin H; Rubio MT; Jindra P; Blaise D; Beelen D; Labussière-Wallet H; Nagler A; Bazarbachi A; Mohty M
Cancer Med; 2022 Feb; 11(4):1068-1080. PubMed ID: 35048553
[TBL] [Abstract][Full Text] [Related]
26. Analysis of FLT3-Activating Mutations in Patients With Acute Myelogenous Leukemia in Jordan: Association With FAB Subtypes and Identification of Subgroups With Poor Prognosis.
Halahleh K; Taqash A; Abdelkhaleq H; Manasrah M; Marie L; Al-Rabi K
Clin Lymphoma Myeloma Leuk; 2021 Jul; 21(7):e588-e597. PubMed ID: 33811005
[TBL] [Abstract][Full Text] [Related]
27. Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia.
Schlenk RF; Döhner K; Krauter J; Fröhling S; Corbacioglu A; Bullinger L; Habdank M; Späth D; Morgan M; Benner A; Schlegelberger B; Heil G; Ganser A; Döhner H;
N Engl J Med; 2008 May; 358(18):1909-18. PubMed ID: 18450602
[TBL] [Abstract][Full Text] [Related]
28. Influence of FLT3-ITD and NPM1 status on allogeneic hematopoietic cell transplant outcomes in patients with cytogenetically normal AML.
Pasic I; Da'na W; Lam W; Law A; Lipton JH; Viswabandya A; Kim DD; Thyagu S; Messner HA; Michelis FV
Eur J Haematol; 2019 Apr; 102(4):368-374. PubMed ID: 30706524
[TBL] [Abstract][Full Text] [Related]
29. Allogeneic hematopoietic stem cell transplantation at the first remission for younger adults with FLT3-internal tandem duplication AML: The JALSG AML209-FLT3-SCT study.
Kawashima N; Ishikawa Y; Atsuta Y; Sawa M; Ozawa Y; Hayashi M; Kohno A; Tomita A; Maeda T; Sakaida E; Usuki K; Hagihara M; Kanamori H; Matsuoka H; Kobayashi M; Asou N; Ohtake S; Matsumura I; Miyazaki Y; Naoe T; Kiyoi H;
Cancer Sci; 2020 Jul; 111(7):2472-2481. PubMed ID: 32391628
[TBL] [Abstract][Full Text] [Related]
30. FLT3-ITD positive acute myeloid leukemia: A retrospective analysis of the role of allogeneic transplant and allelic ratio in patient management.
Taylor E; Morris K; Ellis M; Marlton P; Baveshi K; Clarey J; Irving I; Cochrane T; Kennedy G
Asia Pac J Clin Oncol; 2018 Dec; 14(6):426-430. PubMed ID: 29383835
[TBL] [Abstract][Full Text] [Related]
31. Gilteritinib as Post-Transplant Maintenance for AML With Internal Tandem Duplication Mutation of
Levis MJ; Hamadani M; Logan B; Jones RJ; Singh AK; Litzow M; Wingard JR; Papadopoulos EB; Perl AE; Soiffer RJ; Ustun C; Ueda Oshima M; Uy GL; Waller EK; Vasu S; Solh M; Mishra A; Muffly L; Kim HJ; Mikesch JH; Najima Y; Onozawa M; Thomson K; Nagler A; Wei AH; Marcucci G; Geller NL; Hasabou N; Delgado D; Rosales M; Hill J; Gill SC; Nuthethi R; King D; Wittsack H; Mendizabal A; Devine SM; Horowitz MM; Chen YB;
J Clin Oncol; 2024 May; 42(15):1766-1775. PubMed ID: 38471061
[TBL] [Abstract][Full Text] [Related]
32. Importance of early detection and follow-up of FLT3 mutations in patients with acute myeloid leukemia.
Colovic N; Tosic N; Aveic S; Djuric M; Milic N; Bumbasirevic V; Colovic M; Pavlovic S
Ann Hematol; 2007 Oct; 86(10):741-7. PubMed ID: 17579862
[TBL] [Abstract][Full Text] [Related]
33. Relapse risk and survival in patients with FLT3 mutated acute myeloid leukemia undergoing stem cell transplantation.
Gaballa S; Saliba R; Oran B; Brammer JE; Chen J; Rondon G; Alousi AM; Kebriaei P; Marin D; Popat UR; Andersson BS; Shpall EJ; Jabbour E; Daver N; Andreeff M; Ravandi F; Cortes J; Patel K; Champlin RE; Ciurea SO
Am J Hematol; 2017 Apr; 92(4):331-337. PubMed ID: 28052408
[TBL] [Abstract][Full Text] [Related]
34. FLT3-ITD with DNMT3A R882 double mutation is a poor prognostic factor in Chinese patients with acute myeloid leukemia after chemotherapy or allogeneic hematopoietic stem cell transplantation.
Tang S; Shen H; Mao X; Dai H; Zhu X; Xue S; Ding Z; Lu J; Wu D; Tang X
Int J Hematol; 2017 Oct; 106(4):552-561. PubMed ID: 28616699
[TBL] [Abstract][Full Text] [Related]
35. FLT3 inhibitors as maintenance therapy post allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia patients with FLT3 mutations: A meta-analysis.
Fei X; Zhang S; Gu J; Wang J
Cancer Med; 2023 Mar; 12(6):6877-6888. PubMed ID: 36411731
[TBL] [Abstract][Full Text] [Related]
36. The impact of cytogenetic risk on the outcomes of allogeneic hematopoietic cell transplantation in patients with relapsed/refractory acute myeloid leukemia: On behalf of the acute leukemia working party (ALWP) of the European group for blood and marrow transplantation (EBMT).
Poiani M; Labopin M; Battipaglia G; Beelen DW; Tischer J; Finke J; Brecht A; Forcade E; Ganser A; Passweg JR; Labussiere-Wallet H; Yakoub-Agha I; Schäfer-Eckart K; Kroeger N; Guffroy B; Ruggeri A; Esteve J; Nagler A; Mohty M
Am J Hematol; 2021 Jan; 96(1):40-50. PubMed ID: 32944990
[TBL] [Abstract][Full Text] [Related]
37. Allogeneic stem cell transplantation benefits for patients ≥ 60 years with acute myeloid leukemia and
Poiré X; Labopin M; Polge E; Passweg J; Craddock C; Blaise D; Cornelissen JJ; Volin L; Russell NH; Socié G; Michallet M; Fegueux N; Chevallier P; Brecht A; Hunault-Berger M; Mohty M; Esteve J; Nagler A
Haematologica; 2018 Feb; 103(2):256-265. PubMed ID: 29242299
[TBL] [Abstract][Full Text] [Related]
38. Predictive value of pretransplantation molecular minimal residual disease assessment by WT1 gene expression in FLT3-positive acute myeloid leukemia.
Candoni A; De Marchi F; Zanini F; Zannier ME; Simeone E; Toffoletti E; Chiarvesio A; Cerno M; Filì C; Patriarca F; Fanin R
Exp Hematol; 2017 May; 49():25-33. PubMed ID: 28159598
[TBL] [Abstract][Full Text] [Related]
39. Role of allogeneic transplantation for FLT3/ITD acute myeloid leukemia: outcomes from 133 consecutive newly diagnosed patients from a single institution.
DeZern AE; Sung A; Kim S; Smith BD; Karp JE; Gore SD; Jones RJ; Fuchs E; Luznik L; McDevitt M; Levis M
Biol Blood Marrow Transplant; 2011 Sep; 17(9):1404-9. PubMed ID: 21324374
[TBL] [Abstract][Full Text] [Related]
40. Improved outcomes among newly diagnosed patients with FMS-like tyrosine kinase 3 internal tandem duplication mutated acute myeloid leukemia treated with contemporary therapy: Revisiting the European LeukemiaNet adverse risk classification.
Reville PK; Sasaki K; Kantarjian HM; Daver NG; Yilmaz M; Dinardo CD; Short NJ; Borthakur G; Pemmaraju N; Mehta RS; Pierce S; Konoplev SN; Khoury JD; Garcia-Manero G; Konopleva MY; Jabbour E; Ravandi F; Kadia TM
Am J Hematol; 2022 Mar; 97(3):329-337. PubMed ID: 34981570
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
